Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06ETI
|
|||
| Former ID |
DCL000415
|
|||
| Drug Name |
ABT-263
|
|||
| Synonyms |
Navitoclax; ABT 263; S1001_Selleck; ABT263, Navitoclax; 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({4-({(1R)-3-morpholin-4-yl-1-[(phenylsulfanyl)methyl]propyl}amino)-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Myelofibrosis [ICD-11: 2A20.2; ICD-10: D47.4] | Phase 3 | [1] | |
| Relapsed or refractory chronic lymphocytic leukaemia [ICD-11: 2A82.0; ICD-10: C83.0, C91.1] | Phase 2 | [2], [3] | ||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Discontinued in Phase 2 | [4] | ||
| Company |
Roche; Genentech
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C47H55ClF3N5O6S3
|
|||
| Canonical SMILES |
CC1(CCC(=C(C1)CN2CCN(CC2)C3=CC=C(C=C3)C(=O)NS(=O)(=O)C4=CC(=C(C=C4)NC(CCN5CCOCC5)CSC6=CC=CC=C6)S(=O)(=O)C(F)(F)F)C7=CC=C(C=C7)Cl)C
|
|||
| InChI |
1S/C47H55ClF3N5O6S3/c1-46(2)20-18-42(34-8-12-37(48)13-9-34)36(31-46)32-55-22-24-56(25-23-55)39-14-10-35(11-15-39)45(57)53-65(60,61)41-16-17-43(44(30-41)64(58,59)47(49,50)51)52-38(19-21-54-26-28-62-29-27-54)33-63-40-6-4-3-5-7-40/h3-17,30,38,52H,18-29,31-33H2,1-2H3,(H,53,57)/t38-/m1/s1
|
|||
| InChIKey |
JLYAXFNOILIKPP-KXQOOQHDSA-N
|
|||
| CAS Number |
CAS 923564-51-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
56311703, 56314453, 57304426, 57504587, 87219189, 87457108, 96099448, 99003698, 99245529, 99246089, 99431767, 99460835, 103640740, 104115920, 124756924, 124899202, 124899203, 125163731, 126583646, 126667000, 126724167, 131465096, 131465716, 134221945, 135263748, 135626669, 135727392, 136920253, 137126833, 141663047, 143499177, 152035716, 152164573, 152240012, 152258081, 152344157, 160646920, 162011689, 162037376, 162202714, 163123180, 163821637, 164194132, 164831796, 174007035, 174531509, 198955115, 204380851, 223388517, 223685382
|
|||
| ChEBI ID |
CHEBI:94128
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04472598) Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis (TRANSFORM-1). U.S. National Institutes of Health. | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8319). | |||
| REF 3 | Clinical pipeline report, company report or official report of Roche (2009). | |||
| REF 4 | Small molecules, big targets: drug discovery faces the protein-protein interaction challenge.Nat Rev Drug Discov. 2016 Aug;15(8):533-50. | |||
| REF 5 | ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo. Mol Cancer Ther. 2008 Oct;7(10):3265-74. | |||
| REF 6 | ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008 May 1;68(9):3421-8. | |||
| REF 7 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.